ConductScience.org, home

Comparison · NCT02688400-503c62ef

Diacerein vs Celecoxib: OARSI Responders

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Diacerein vs Celecoxib: OARSI Responders. Trial comparisons, record NCT02688400-503c62ef. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02688400-503c62ef

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5410.4690.612wilson
Risk in group 20.5190.4470.589wilson
Risk difference, group 1 minus group 20.0223-0.07870.123newcombe hybrid score
Risk ratio, group 1 over group 21.040.8611.26log
Odds ratio, group 1 over group 21.090.7271.65log
Number needed to treat, for one more participant with the outcome on Diacerein than on Celecoxib44.9from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Diacerein
One placebo capsule once daily in the morning (breakfast) and one diacerein 50 mg capsule once daily in the evening (dinner) for the first month, then diacerein capsules twice daily with meals in the morning (breakfast) and the evening (dinner).~Diacerein~Placebo
99183OG000
Group 2CelecoxibOne celecoxib 200 mg capsule once daily in the morning (breakfast) and one placebo capsule once daily in the evening (dinner).~Celecoxib~Placebo97187OG001

Outcome

Type
SECONDARY
Title
OARSI Responders
Description
Osteoarthritis Research Society International (OARSI) Responders
Time frame
Day 182 or early termination
Population
Intentio-to-treat

Source ClinicalTrials.gov

Trial

Title
Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis
NCT number
NCT02688400
Phases
PHASE3
Conditions
Osteoarthritis, Osteoarthritis, Knee
Interventions
Diacerein, Celecoxib, Placebo
Lead sponsor
TRB Chemedica International SA
Results first posted
2023-12-01

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02688400-503c62ef